| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Berylliosis | 79 | 2026 | 204 | 15.040 |
Why?
|
| Beryllium | 62 | 2026 | 163 | 9.570 |
Why?
|
| Sarcoidosis | 43 | 2026 | 164 | 9.390 |
Why?
|
| Sarcoidosis, Pulmonary | 31 | 2026 | 100 | 8.920 |
Why?
|
| Occupational Exposure | 39 | 2025 | 356 | 5.750 |
Why?
|
| HLA-DP beta-Chains | 15 | 2025 | 88 | 2.940 |
Why?
|
| Occupational Diseases | 9 | 2025 | 164 | 2.510 |
Why?
|
| Bacteria | 13 | 2025 | 766 | 2.480 |
Why?
|
| Gastrointestinal Microbiome | 12 | 2025 | 767 | 2.400 |
Why?
|
| Bronchoalveolar Lavage Fluid | 28 | 2026 | 641 | 2.270 |
Why?
|
| Salmonella typhimurium | 7 | 2025 | 193 | 1.860 |
Why?
|
| Genetic Predisposition to Disease | 19 | 2026 | 2455 | 1.850 |
Why?
|
| Microbiota | 9 | 2025 | 724 | 1.840 |
Why?
|
| Chronic Disease | 50 | 2026 | 1824 | 1.820 |
Why?
|
| Lung Diseases | 10 | 2022 | 787 | 1.640 |
Why?
|
| Lung | 36 | 2026 | 4119 | 1.600 |
Why?
|
| Biomarkers | 16 | 2026 | 4329 | 1.470 |
Why?
|
| Polymorphism, Genetic | 13 | 2021 | 611 | 1.320 |
Why?
|
| Humans | 195 | 2026 | 145625 | 1.320 |
Why?
|
| Tomography, X-Ray Computed | 11 | 2026 | 2766 | 1.290 |
Why?
|
| Symbiosis | 4 | 2025 | 71 | 1.280 |
Why?
|
| Bacteria, Anaerobic | 3 | 2025 | 25 | 1.240 |
Why?
|
| Leukocytes, Mononuclear | 10 | 2026 | 585 | 1.230 |
Why?
|
| Adrenal Cortex Hormones | 5 | 2020 | 483 | 1.180 |
Why?
|
| CD4-Positive T-Lymphocytes | 20 | 2026 | 1148 | 1.130 |
Why?
|
| HLA-DP Antigens | 9 | 2011 | 32 | 1.070 |
Why?
|
| Environmental Exposure | 8 | 2026 | 578 | 1.030 |
Why?
|
| Lymphocytes | 13 | 2020 | 379 | 1.030 |
Why?
|
| Middle Aged | 85 | 2026 | 36359 | 1.030 |
Why?
|
| CD55 Antigens | 2 | 2026 | 31 | 1.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 15 | 2026 | 1223 | 1.000 |
Why?
|
| Pulmonary Fibrosis | 4 | 2026 | 395 | 0.990 |
Why?
|
| HLA-DRB1 Chains | 4 | 2025 | 109 | 0.980 |
Why?
|
| Proteomics | 8 | 2026 | 1202 | 0.970 |
Why?
|
| Male | 102 | 2026 | 73014 | 0.940 |
Why?
|
| Case-Control Studies | 25 | 2024 | 3633 | 0.940 |
Why?
|
| Anti-Bacterial Agents | 10 | 2025 | 1935 | 0.880 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 5 | 2022 | 926 | 0.880 |
Why?
|
| Female | 99 | 2026 | 79080 | 0.870 |
Why?
|
| Biotechnology | 1 | 2025 | 45 | 0.860 |
Why?
|
| Lymphocyte Activation | 19 | 2026 | 1136 | 0.840 |
Why?
|
| Proton Pump Inhibitors | 1 | 2025 | 101 | 0.840 |
Why?
|
| Clostridium Infections | 1 | 2025 | 73 | 0.830 |
Why?
|
| Immunoglobulin E | 1 | 2026 | 315 | 0.820 |
Why?
|
| Alleles | 12 | 2025 | 900 | 0.820 |
Why?
|
| High-Throughput Screening Assays | 2 | 2023 | 179 | 0.810 |
Why?
|
| Granuloma | 7 | 2024 | 96 | 0.800 |
Why?
|
| Food Hypersensitivity | 1 | 2026 | 165 | 0.790 |
Why?
|
| Gastrointestinal Tract | 3 | 2014 | 203 | 0.790 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 3 | 2017 | 344 | 0.780 |
Why?
|
| Adult | 68 | 2026 | 40821 | 0.780 |
Why?
|
| Gene Expression Regulation | 6 | 2021 | 2591 | 0.780 |
Why?
|
| Genotype | 16 | 2025 | 1866 | 0.770 |
Why?
|
| Gene-Environment Interaction | 2 | 2026 | 188 | 0.760 |
Why?
|
| Feces | 7 | 2025 | 494 | 0.760 |
Why?
|
| Alveolitis, Extrinsic Allergic | 6 | 2021 | 96 | 0.740 |
Why?
|
| Skin Diseases | 2 | 2024 | 144 | 0.740 |
Why?
|
| Nicotine | 2 | 2021 | 334 | 0.730 |
Why?
|
| Lipopolysaccharide Receptors | 3 | 2015 | 88 | 0.730 |
Why?
|
| Phenotype | 13 | 2026 | 3186 | 0.720 |
Why?
|
| Bacterial Infections | 1 | 2024 | 246 | 0.700 |
Why?
|
| Drug Resistance, Bacterial | 2 | 2025 | 185 | 0.690 |
Why?
|
| Disease Progression | 10 | 2026 | 2857 | 0.680 |
Why?
|
| Pulmonary Diffusing Capacity | 4 | 2026 | 78 | 0.680 |
Why?
|
| Hypersensitivity | 6 | 2014 | 253 | 0.640 |
Why?
|
| DNA Methylation | 4 | 2025 | 721 | 0.610 |
Why?
|
| Cell Proliferation | 14 | 2026 | 2497 | 0.610 |
Why?
|
| Mesalamine | 2 | 2017 | 9 | 0.600 |
Why?
|
| Aged | 48 | 2025 | 26251 | 0.600 |
Why?
|
| HLA Antigens | 3 | 2015 | 241 | 0.600 |
Why?
|
| Drug Interactions | 1 | 2021 | 403 | 0.600 |
Why?
|
| Ecosystem | 1 | 2023 | 483 | 0.580 |
Why?
|
| Receptors, IgG | 2 | 2018 | 77 | 0.560 |
Why?
|
| Biomedical Research | 4 | 2022 | 724 | 0.560 |
Why?
|
| Allergens | 5 | 2025 | 390 | 0.560 |
Why?
|
| Respiratory Hypersensitivity | 5 | 2012 | 65 | 0.560 |
Why?
|
| Immunity, Cellular | 2 | 2017 | 277 | 0.540 |
Why?
|
| Respiratory Function Tests | 10 | 2026 | 543 | 0.530 |
Why?
|
| Cytokines | 8 | 2019 | 2079 | 0.520 |
Why?
|
| Genome-Wide Association Study | 8 | 2026 | 1526 | 0.510 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2018 | 195 | 0.510 |
Why?
|
| Dyspnea | 2 | 2021 | 251 | 0.500 |
Why?
|
| Cough | 1 | 2018 | 123 | 0.500 |
Why?
|
| T-Lymphocytes | 5 | 2026 | 2007 | 0.490 |
Why?
|
| Longitudinal Studies | 9 | 2026 | 3005 | 0.490 |
Why?
|
| Asthma | 3 | 2020 | 1800 | 0.480 |
Why?
|
| Gene Expression Profiling | 3 | 2021 | 1790 | 0.470 |
Why?
|
| Military Personnel | 1 | 2024 | 715 | 0.460 |
Why?
|
| alpha 1-Antitrypsin Deficiency | 3 | 2022 | 61 | 0.460 |
Why?
|
| Proteins | 3 | 2020 | 1021 | 0.460 |
Why?
|
| Host-Pathogen Interactions | 5 | 2024 | 366 | 0.460 |
Why?
|
| Macrophages, Alveolar | 4 | 2020 | 377 | 0.450 |
Why?
|
| Spirometry | 3 | 2026 | 234 | 0.450 |
Why?
|
| Transcriptome | 5 | 2026 | 1066 | 0.440 |
Why?
|
| Radiography, Thoracic | 4 | 2026 | 174 | 0.440 |
Why?
|
| Bronchoalveolar Lavage | 6 | 2022 | 90 | 0.440 |
Why?
|
| Immunization | 4 | 2008 | 375 | 0.430 |
Why?
|
| Granulocytes | 1 | 2014 | 82 | 0.430 |
Why?
|
| Hydrogenase | 1 | 2014 | 12 | 0.430 |
Why?
|
| Animals | 31 | 2026 | 38030 | 0.420 |
Why?
|
| Salmonella Infections, Animal | 1 | 2014 | 39 | 0.420 |
Why?
|
| Anaerobiosis | 2 | 2025 | 65 | 0.420 |
Why?
|
| Salmonella Infections | 4 | 2025 | 58 | 0.420 |
Why?
|
| Severity of Illness Index | 11 | 2024 | 2910 | 0.400 |
Why?
|
| Mycophenolic Acid | 1 | 2014 | 117 | 0.400 |
Why?
|
| Chemokine CCL3 | 2 | 2026 | 26 | 0.400 |
Why?
|
| Polymorphism, Single Nucleotide | 7 | 2026 | 2228 | 0.400 |
Why?
|
| Particle Size | 4 | 2014 | 382 | 0.400 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2014 | 262 | 0.390 |
Why?
|
| Dendritic Cells | 3 | 2026 | 507 | 0.390 |
Why?
|
| Occupational Health | 3 | 2025 | 212 | 0.390 |
Why?
|
| Immunity, Innate | 4 | 2022 | 843 | 0.390 |
Why?
|
| Mice | 19 | 2026 | 18266 | 0.380 |
Why?
|
| Models, Immunological | 3 | 2013 | 100 | 0.380 |
Why?
|
| Odds Ratio | 6 | 2020 | 1070 | 0.370 |
Why?
|
| Periodicals as Topic | 1 | 2015 | 209 | 0.360 |
Why?
|
| Escherichia coli | 4 | 2025 | 831 | 0.360 |
Why?
|
| Cardiomyopathies | 5 | 2020 | 339 | 0.360 |
Why?
|
| Risk Factors | 16 | 2026 | 10840 | 0.350 |
Why?
|
| Immunosuppressive Agents | 3 | 2024 | 824 | 0.350 |
Why?
|
| Air Pollutants, Occupational | 2 | 2010 | 41 | 0.350 |
Why?
|
| Colitis | 1 | 2014 | 280 | 0.340 |
Why?
|
| Mandibular Fractures | 2 | 2022 | 16 | 0.340 |
Why?
|
| Glutamic Acid | 4 | 2007 | 255 | 0.340 |
Why?
|
| Diagnosis, Differential | 6 | 2024 | 1500 | 0.330 |
Why?
|
| Medical Laboratory Personnel | 1 | 2010 | 6 | 0.320 |
Why?
|
| Mandibular Nerve | 2 | 2020 | 5 | 0.310 |
Why?
|
| Forced Expiratory Volume | 4 | 2018 | 451 | 0.310 |
Why?
|
| Pulmonary Emphysema | 2 | 2023 | 276 | 0.310 |
Why?
|
| Endotoxins | 2 | 2010 | 215 | 0.310 |
Why?
|
| Vital Capacity | 4 | 2019 | 293 | 0.310 |
Why?
|
| Receptors, CCR5 | 1 | 2010 | 59 | 0.300 |
Why?
|
| Quality of Life | 8 | 2024 | 3187 | 0.300 |
Why?
|
| Antibodies, Monoclonal | 5 | 2012 | 1511 | 0.290 |
Why?
|
| Th1 Cells | 3 | 2013 | 138 | 0.290 |
Why?
|
| Smoking | 6 | 2021 | 1478 | 0.290 |
Why?
|
| Systems Biology | 2 | 2021 | 68 | 0.280 |
Why?
|
| Aged, 80 and over | 16 | 2025 | 8351 | 0.280 |
Why?
|
| United States | 15 | 2025 | 16041 | 0.280 |
Why?
|
| Lung Diseases, Interstitial | 2 | 2020 | 677 | 0.280 |
Why?
|
| Interferon-gamma | 8 | 2021 | 780 | 0.280 |
Why?
|
| HLA-DR Antigens | 4 | 2015 | 211 | 0.280 |
Why?
|
| Klebsiella pneumoniae | 2 | 2025 | 48 | 0.270 |
Why?
|
| Exosomes | 2 | 2021 | 103 | 0.270 |
Why?
|
| Glutathione | 3 | 2017 | 369 | 0.270 |
Why?
|
| Logistic Models | 7 | 2020 | 2112 | 0.270 |
Why?
|
| Administration, Inhalation | 2 | 2020 | 567 | 0.260 |
Why?
|
| RNA | 3 | 2023 | 925 | 0.260 |
Why?
|
| Cell Communication | 2 | 2026 | 327 | 0.250 |
Why?
|
| Aerosols | 3 | 2026 | 146 | 0.250 |
Why?
|
| Multicenter Studies as Topic | 2 | 2026 | 413 | 0.250 |
Why?
|
| Janus Kinase 2 | 1 | 2026 | 31 | 0.240 |
Why?
|
| Cohort Studies | 5 | 2026 | 6045 | 0.240 |
Why?
|
| Lipopolysaccharides | 4 | 2025 | 861 | 0.240 |
Why?
|
| STAT1 Transcription Factor | 1 | 2026 | 68 | 0.240 |
Why?
|
| Bacterial Proteins | 3 | 2025 | 976 | 0.240 |
Why?
|
| Retrospective Studies | 10 | 2024 | 17291 | 0.240 |
Why?
|
| Epitopes, T-Lymphocyte | 3 | 2021 | 175 | 0.230 |
Why?
|
| Reactive Oxygen Species | 3 | 2025 | 610 | 0.230 |
Why?
|
| Disease Models, Animal | 6 | 2026 | 4565 | 0.230 |
Why?
|
| Bronchoscopy | 5 | 2021 | 227 | 0.230 |
Why?
|
| Mice, Inbred C57BL | 7 | 2025 | 6021 | 0.230 |
Why?
|
| Bacteroides | 2 | 2025 | 20 | 0.230 |
Why?
|
| Chemokine CCL4 | 2 | 2026 | 31 | 0.230 |
Why?
|
| Marketing | 1 | 2025 | 23 | 0.230 |
Why?
|
| Gammaproteobacteria | 1 | 2025 | 13 | 0.230 |
Why?
|
| Omeprazole | 1 | 2025 | 9 | 0.230 |
Why?
|
| Magnetic Resonance Imaging | 6 | 2022 | 3917 | 0.230 |
Why?
|
| Sputum | 3 | 2025 | 302 | 0.230 |
Why?
|
| Sunscreening Agents | 1 | 2025 | 25 | 0.220 |
Why?
|
| Research Design | 2 | 2026 | 1139 | 0.220 |
Why?
|
| Cause of Death | 2 | 2019 | 455 | 0.220 |
Why?
|
| Air Pollution | 2 | 2025 | 314 | 0.220 |
Why?
|
| T-Lymphocyte Subsets | 7 | 2013 | 415 | 0.220 |
Why?
|
| Intestines | 3 | 2025 | 351 | 0.220 |
Why?
|
| Macrophages | 5 | 2026 | 1530 | 0.220 |
Why?
|
| Bioreactors | 1 | 2025 | 49 | 0.220 |
Why?
|
| Mortality | 2 | 2019 | 375 | 0.220 |
Why?
|
| Membrane Glycoproteins | 1 | 2007 | 495 | 0.210 |
Why?
|
| Biopsy | 5 | 2020 | 1073 | 0.210 |
Why?
|
| Cluster Analysis | 2 | 2026 | 494 | 0.210 |
Why?
|
| Spiro Compounds | 1 | 2024 | 17 | 0.210 |
Why?
|
| Pyrroles | 1 | 2025 | 221 | 0.210 |
Why?
|
| Genetic Variation | 3 | 2023 | 992 | 0.210 |
Why?
|
| Ketones | 1 | 2024 | 51 | 0.200 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2025 | 538 | 0.200 |
Why?
|
| Central Nervous System Diseases | 2 | 2021 | 73 | 0.200 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2025 | 533 | 0.200 |
Why?
|
| Prognosis | 4 | 2026 | 4331 | 0.200 |
Why?
|
| Chemokine CX3CL1 | 1 | 2023 | 25 | 0.200 |
Why?
|
| Fluorocarbons | 1 | 2025 | 122 | 0.200 |
Why?
|
| Benzodioxoles | 1 | 2025 | 164 | 0.200 |
Why?
|
| Peritonitis | 1 | 2024 | 82 | 0.200 |
Why?
|
| Adolescent | 13 | 2026 | 22451 | 0.200 |
Why?
|
| Environmental Pollutants | 1 | 2025 | 142 | 0.200 |
Why?
|
| Escherichia coli Proteins | 1 | 2025 | 200 | 0.200 |
Why?
|
| Neopterin | 1 | 2003 | 13 | 0.200 |
Why?
|
| Metagenomics | 2 | 2023 | 153 | 0.190 |
Why?
|
| Spirulina | 1 | 2023 | 4 | 0.190 |
Why?
|
| Quinolones | 1 | 2025 | 204 | 0.190 |
Why?
|
| Cysteine Proteases | 1 | 2023 | 8 | 0.190 |
Why?
|
| Genetic Association Studies | 2 | 2023 | 376 | 0.190 |
Why?
|
| Mandible | 2 | 2020 | 73 | 0.190 |
Why?
|
| Aminophenols | 1 | 2025 | 204 | 0.190 |
Why?
|
| Somatomedins | 1 | 2022 | 28 | 0.190 |
Why?
|
| Alkanesulfonic Acids | 1 | 2022 | 37 | 0.180 |
Why?
|
| Stress, Physiological | 1 | 2025 | 449 | 0.180 |
Why?
|
| Inhalation Exposure | 3 | 2020 | 103 | 0.180 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2003 | 365 | 0.180 |
Why?
|
| Double-Blind Method | 3 | 2017 | 2064 | 0.180 |
Why?
|
| Dicumarol | 1 | 2021 | 3 | 0.180 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 2 | 2022 | 103 | 0.170 |
Why?
|
| Erythromycin | 1 | 2021 | 19 | 0.170 |
Why?
|
| Cell Membrane | 1 | 2025 | 701 | 0.170 |
Why?
|
| Duloxetine Hydrochloride | 1 | 2021 | 10 | 0.170 |
Why?
|
| Germ-Free Life | 1 | 2021 | 33 | 0.170 |
Why?
|
| Aspergillus nidulans | 1 | 2021 | 6 | 0.170 |
Why?
|
| Tetracyclines | 1 | 2021 | 16 | 0.170 |
Why?
|
| Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2025 | 373 | 0.170 |
Why?
|
| Dust | 1 | 2022 | 92 | 0.170 |
Why?
|
| Immunologic Tests | 1 | 2001 | 16 | 0.170 |
Why?
|
| Macrolides | 1 | 2021 | 68 | 0.170 |
Why?
|
| Nuclear Weapons | 2 | 2011 | 7 | 0.170 |
Why?
|
| Air Pollutants | 2 | 2025 | 406 | 0.170 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2024 | 253 | 0.170 |
Why?
|
| Hydrogen Sulfide | 1 | 2001 | 47 | 0.160 |
Why?
|
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 20 | 0.160 |
Why?
|
| Silicon Dioxide | 1 | 2022 | 118 | 0.160 |
Why?
|
| Circulating MicroRNA | 1 | 2021 | 26 | 0.160 |
Why?
|
| Maximum Allowable Concentration | 1 | 2020 | 15 | 0.160 |
Why?
|
| Societies | 1 | 2020 | 40 | 0.160 |
Why?
|
| Immunoglobulin G | 4 | 2022 | 899 | 0.160 |
Why?
|
| T-Lymphocytes, Regulatory | 4 | 2021 | 411 | 0.160 |
Why?
|
| Arthroplasty, Replacement | 1 | 2021 | 47 | 0.160 |
Why?
|
| Salmo salar | 1 | 2020 | 1 | 0.160 |
Why?
|
| Aquaculture | 1 | 2020 | 3 | 0.160 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2025 | 774 | 0.160 |
Why?
|
| Smoke | 1 | 2021 | 149 | 0.160 |
Why?
|
| Interleukin-4 | 1 | 2001 | 207 | 0.160 |
Why?
|
| Personal Protective Equipment | 1 | 2020 | 58 | 0.150 |
Why?
|
| Unemployment | 1 | 2020 | 43 | 0.150 |
Why?
|
| B-Lymphocyte Subsets | 1 | 2020 | 78 | 0.150 |
Why?
|
| Lingual Nerve | 1 | 2019 | 1 | 0.150 |
Why?
|
| Communicable Diseases | 1 | 2022 | 165 | 0.150 |
Why?
|
| Sensitivity and Specificity | 5 | 2013 | 1992 | 0.150 |
Why?
|
| Masks | 1 | 2020 | 70 | 0.150 |
Why?
|
| Insulin Infusion Systems | 1 | 2024 | 488 | 0.150 |
Why?
|
| Microbial Interactions | 1 | 2019 | 19 | 0.150 |
Why?
|
| Young Adult | 11 | 2025 | 14240 | 0.150 |
Why?
|
| Microbial Sensitivity Tests | 3 | 2025 | 367 | 0.150 |
Why?
|
| Retinal Artery | 1 | 2019 | 17 | 0.150 |
Why?
|
| Extracellular Vesicles | 1 | 2022 | 175 | 0.150 |
Why?
|
| Inflammation Mediators | 3 | 2012 | 507 | 0.150 |
Why?
|
| Electrocardiography | 2 | 2020 | 666 | 0.150 |
Why?
|
| Iron | 1 | 2021 | 359 | 0.140 |
Why?
|
| Eating | 1 | 2021 | 386 | 0.140 |
Why?
|
| Electrophysiologic Techniques, Cardiac | 1 | 2019 | 82 | 0.140 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 1999 | 57 | 0.140 |
Why?
|
| Pneumoconiosis | 1 | 2019 | 20 | 0.140 |
Why?
|
| Biological Evolution | 2 | 2013 | 471 | 0.140 |
Why?
|
| Income | 1 | 2020 | 205 | 0.140 |
Why?
|
| Antioxidants | 2 | 2016 | 544 | 0.140 |
Why?
|
| Regression Analysis | 3 | 2019 | 994 | 0.140 |
Why?
|
| Propensity Score | 1 | 2020 | 370 | 0.140 |
Why?
|
| Kidney Diseases | 2 | 2020 | 427 | 0.140 |
Why?
|
| Immunologic Memory | 4 | 2013 | 369 | 0.140 |
Why?
|
| Virulence Factors | 3 | 2014 | 175 | 0.140 |
Why?
|
| Residual Volume | 1 | 2018 | 5 | 0.140 |
Why?
|
| Chemokines | 2 | 2019 | 217 | 0.140 |
Why?
|
| Gene Expression | 2 | 2021 | 1461 | 0.130 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2016 | 333 | 0.130 |
Why?
|
| Algorithms | 2 | 2020 | 1843 | 0.130 |
Why?
|
| Metagenome | 2 | 2022 | 127 | 0.130 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 2020 | 189 | 0.130 |
Why?
|
| Cell Division | 7 | 2025 | 735 | 0.130 |
Why?
|
| Immunologic Factors | 1 | 2020 | 244 | 0.130 |
Why?
|
| In Vitro Techniques | 2 | 2018 | 1041 | 0.130 |
Why?
|
| Microbial Viability | 1 | 2018 | 82 | 0.130 |
Why?
|
| Cost of Illness | 1 | 2020 | 322 | 0.130 |
Why?
|
| Dietary Fats | 1 | 2019 | 307 | 0.130 |
Why?
|
| September 11 Terrorist Attacks | 1 | 2017 | 31 | 0.130 |
Why?
|
| Monocytes | 2 | 2023 | 538 | 0.130 |
Why?
|
| Dental Technicians | 2 | 2014 | 2 | 0.130 |
Why?
|
| Reproducibility of Results | 4 | 2021 | 3396 | 0.130 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2018 | 96 | 0.130 |
Why?
|
| Betacoronavirus | 1 | 2020 | 288 | 0.130 |
Why?
|
| Diabetes Mellitus, Type 1 | 3 | 2024 | 3930 | 0.120 |
Why?
|
| Liver Diseases | 1 | 2020 | 298 | 0.120 |
Why?
|
| Arthritis, Juvenile | 1 | 2017 | 64 | 0.120 |
Why?
|
| HLA-DQ Antigens | 2 | 2010 | 171 | 0.120 |
Why?
|
| Cellular Senescence | 1 | 2019 | 225 | 0.120 |
Why?
|
| Firefighters | 1 | 2017 | 47 | 0.120 |
Why?
|
| RNA, Ribosomal, 16S | 3 | 2025 | 507 | 0.120 |
Why?
|
| Ventricular Function, Right | 1 | 2019 | 300 | 0.120 |
Why?
|
| Pilot Projects | 2 | 2020 | 1878 | 0.120 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2019 | 358 | 0.120 |
Why?
|
| Promoter Regions, Genetic | 3 | 2019 | 1236 | 0.120 |
Why?
|
| Biological Products | 1 | 2020 | 257 | 0.120 |
Why?
|
| Congresses as Topic | 1 | 2018 | 226 | 0.120 |
Why?
|
| Clinical Decision-Making | 1 | 2020 | 364 | 0.120 |
Why?
|
| Pyridines | 2 | 2025 | 606 | 0.120 |
Why?
|
| Genome, Human | 1 | 2019 | 425 | 0.120 |
Why?
|
| Banking, Personal | 1 | 2016 | 2 | 0.120 |
Why?
|
| Antipsychotic Agents | 1 | 2018 | 178 | 0.120 |
Why?
|
| Disease Management | 1 | 2020 | 649 | 0.120 |
Why?
|
| Global Health | 2 | 2018 | 402 | 0.120 |
Why?
|
| Positron-Emission Tomography | 2 | 2020 | 342 | 0.120 |
Why?
|
| Deoxyguanosine | 1 | 2016 | 25 | 0.120 |
Why?
|
| Predictive Value of Tests | 5 | 2019 | 2097 | 0.120 |
Why?
|
| Action Potentials | 1 | 2019 | 498 | 0.120 |
Why?
|
| Health Care Sector | 1 | 2016 | 25 | 0.120 |
Why?
|
| Poisson Distribution | 1 | 2016 | 77 | 0.120 |
Why?
|
| MicroRNAs | 2 | 2024 | 695 | 0.120 |
Why?
|
| Death Certificates | 1 | 2016 | 32 | 0.120 |
Why?
|
| Ventricular Function, Left | 1 | 2019 | 541 | 0.110 |
Why?
|
| Diet | 2 | 2021 | 1271 | 0.110 |
Why?
|
| Adaptive Immunity | 2 | 2019 | 172 | 0.110 |
Why?
|
| Transcription, Genetic | 2 | 2016 | 1429 | 0.110 |
Why?
|
| Exercise Tolerance | 1 | 2018 | 288 | 0.110 |
Why?
|
| Lung Injury | 1 | 2019 | 262 | 0.110 |
Why?
|
| Cystic Fibrosis | 1 | 2025 | 1164 | 0.110 |
Why?
|
| Decision Support Techniques | 1 | 2020 | 473 | 0.110 |
Why?
|
| Heart Rate | 1 | 2019 | 844 | 0.110 |
Why?
|
| Drug Administration Schedule | 2 | 2014 | 782 | 0.110 |
Why?
|
| Mass Screening | 2 | 2018 | 1300 | 0.110 |
Why?
|
| Pandemics | 2 | 2022 | 1700 | 0.110 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 387 | 0.110 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 379 | 0.110 |
Why?
|
| Commerce | 1 | 2016 | 80 | 0.110 |
Why?
|
| Acetylcysteine | 1 | 2016 | 139 | 0.110 |
Why?
|
| Streptomycin | 1 | 2014 | 18 | 0.110 |
Why?
|
| Cecum | 1 | 2014 | 37 | 0.110 |
Why?
|
| International Classification of Diseases | 1 | 2016 | 142 | 0.110 |
Why?
|
| Hypoglycemic Agents | 1 | 2024 | 1411 | 0.110 |
Why?
|
| Patch Tests | 3 | 2021 | 61 | 0.110 |
Why?
|
| Drug Evaluation | 1 | 2014 | 78 | 0.110 |
Why?
|
| Metals | 1 | 2016 | 137 | 0.110 |
Why?
|
| Toll-Like Receptor 4 | 2 | 2025 | 277 | 0.110 |
Why?
|
| Enterococcus faecium | 2 | 2025 | 22 | 0.110 |
Why?
|
| Glucocorticoids | 2 | 2020 | 536 | 0.110 |
Why?
|
| Cells, Cultured | 7 | 2013 | 4112 | 0.100 |
Why?
|
| Environmental Monitoring | 2 | 2014 | 346 | 0.100 |
Why?
|
| Granulomatous Disease, Chronic | 1 | 2014 | 49 | 0.100 |
Why?
|
| Apoptosis | 4 | 2005 | 2436 | 0.100 |
Why?
|
| CD40 Antigens | 1 | 2014 | 67 | 0.100 |
Why?
|
| Sex Factors | 2 | 2021 | 2101 | 0.100 |
Why?
|
| Child | 6 | 2026 | 22638 | 0.100 |
Why?
|
| Heart Diseases | 1 | 2017 | 341 | 0.100 |
Why?
|
| Metallurgy | 1 | 2014 | 9 | 0.100 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2016 | 751 | 0.100 |
Why?
|
| Population Surveillance | 3 | 2009 | 477 | 0.100 |
Why?
|
| Israel | 1 | 2014 | 45 | 0.100 |
Why?
|
| Haplotypes | 4 | 2010 | 505 | 0.100 |
Why?
|
| Colorado | 4 | 2020 | 4588 | 0.100 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 2 | 2014 | 330 | 0.100 |
Why?
|
| Genetic Markers | 3 | 2021 | 337 | 0.100 |
Why?
|
| Insulin | 1 | 2024 | 2524 | 0.100 |
Why?
|
| B-Lymphocytes | 1 | 2019 | 884 | 0.100 |
Why?
|
| Models, Theoretical | 2 | 2014 | 558 | 0.100 |
Why?
|
| Prednisone | 1 | 2014 | 229 | 0.100 |
Why?
|
| Oxidative Stress | 3 | 2016 | 1367 | 0.100 |
Why?
|
| Occupational Health Services | 1 | 2013 | 36 | 0.100 |
Why?
|
| Imidazoles | 1 | 2014 | 244 | 0.100 |
Why?
|
| Mice, Transgenic | 3 | 2026 | 2131 | 0.100 |
Why?
|
| Teaching | 1 | 2016 | 243 | 0.100 |
Why?
|
| Phagocytosis | 1 | 2015 | 298 | 0.100 |
Why?
|
| Myocardial Infarction | 1 | 2021 | 1212 | 0.090 |
Why?
|
| Liver | 1 | 2021 | 1859 | 0.090 |
Why?
|
| Enzyme Activation | 1 | 2014 | 758 | 0.090 |
Why?
|
| Pulmonary Gas Exchange | 2 | 2004 | 117 | 0.090 |
Why?
|
| Membrane Proteins | 2 | 2020 | 1130 | 0.090 |
Why?
|
| Signal Transduction | 1 | 2026 | 5234 | 0.090 |
Why?
|
| Nickel | 1 | 2013 | 63 | 0.090 |
Why?
|
| CTLA-4 Antigen | 1 | 2013 | 105 | 0.090 |
Why?
|
| MAP Kinase Signaling System | 1 | 2014 | 306 | 0.090 |
Why?
|
| NF-kappa B | 2 | 2014 | 674 | 0.090 |
Why?
|
| Industry | 2 | 2011 | 43 | 0.090 |
Why?
|
| o-Phthalaldehyde | 1 | 2012 | 3 | 0.090 |
Why?
|
| Static Electricity | 1 | 2012 | 113 | 0.090 |
Why?
|
| Dermatitis, Allergic Contact | 1 | 2013 | 74 | 0.090 |
Why?
|
| Linkage Disequilibrium | 2 | 2010 | 257 | 0.090 |
Why?
|
| Epidermis | 1 | 2012 | 72 | 0.090 |
Why?
|
| Radiopharmaceuticals | 1 | 2013 | 210 | 0.090 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2013 | 165 | 0.090 |
Why?
|
| Infliximab | 1 | 2012 | 107 | 0.090 |
Why?
|
| Ceftriaxone | 1 | 2012 | 21 | 0.090 |
Why?
|
| Societies, Medical | 3 | 2025 | 901 | 0.090 |
Why?
|
| Ciprofloxacin | 1 | 2012 | 31 | 0.090 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2012 | 162 | 0.090 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 1 | 2019 | 697 | 0.090 |
Why?
|
| Risk Assessment | 4 | 2020 | 3678 | 0.090 |
Why?
|
| Drug Therapy, Combination | 1 | 2014 | 1034 | 0.090 |
Why?
|
| Amino Acid Substitution | 1 | 2012 | 295 | 0.090 |
Why?
|
| DNA | 3 | 2016 | 1418 | 0.080 |
Why?
|
| Mutation | 3 | 2025 | 4082 | 0.080 |
Why?
|
| Treatment Outcome | 5 | 2024 | 11744 | 0.080 |
Why?
|
| Surveys and Questionnaires | 4 | 2021 | 6050 | 0.080 |
Why?
|
| Psoriasis | 1 | 2012 | 110 | 0.080 |
Why?
|
| Gene Frequency | 3 | 2010 | 495 | 0.080 |
Why?
|
| Receptors, Cell Surface | 3 | 2020 | 371 | 0.080 |
Why?
|
| Metabolomics | 3 | 2023 | 737 | 0.080 |
Why?
|
| Polymerase Chain Reaction | 2 | 2011 | 1030 | 0.080 |
Why?
|
| Diarrhea | 1 | 2012 | 190 | 0.080 |
Why?
|
| Interleukins | 1 | 2012 | 247 | 0.080 |
Why?
|
| fas Receptor | 2 | 2008 | 91 | 0.080 |
Why?
|
| Forced Expiratory Flow Rates | 1 | 2010 | 10 | 0.080 |
Why?
|
| Endocytosis | 1 | 1991 | 168 | 0.080 |
Why?
|
| Trigeminal Nerve Injuries | 2 | 2020 | 3 | 0.080 |
Why?
|
| Genes, MHC Class II | 1 | 2010 | 77 | 0.080 |
Why?
|
| Occupations | 2 | 2019 | 50 | 0.080 |
Why?
|
| Phosphorylation | 1 | 2014 | 1717 | 0.080 |
Why?
|
| Up-Regulation | 3 | 2008 | 840 | 0.080 |
Why?
|
| Sulfasalazine | 1 | 2009 | 22 | 0.080 |
Why?
|
| Diagnostic Errors | 1 | 2011 | 178 | 0.070 |
Why?
|
| Antigens | 2 | 2021 | 350 | 0.070 |
Why?
|
| Hospitalization | 1 | 2020 | 2468 | 0.070 |
Why?
|
| Tumor Necrosis Factor Receptor Superfamily, Member 7 | 1 | 2009 | 30 | 0.070 |
Why?
|
| Exercise Test | 2 | 2003 | 634 | 0.070 |
Why?
|
| Virulence | 2 | 2025 | 287 | 0.070 |
Why?
|
| Homozygote | 2 | 2007 | 196 | 0.070 |
Why?
|
| Uveitis | 1 | 2010 | 151 | 0.070 |
Why?
|
| Multivariate Analysis | 3 | 2020 | 1531 | 0.070 |
Why?
|
| Epigenesis, Genetic | 2 | 2025 | 705 | 0.070 |
Why?
|
| Tumor Necrosis Factor Receptor Superfamily, Member 9 | 1 | 2008 | 23 | 0.070 |
Why?
|
| Animals, Laboratory | 1 | 2008 | 22 | 0.070 |
Why?
|
| HLA-D Antigens | 1 | 2008 | 30 | 0.070 |
Why?
|
| Proto-Oncogene Proteins | 1 | 1991 | 615 | 0.070 |
Why?
|
| Butyrophilins | 1 | 2007 | 5 | 0.070 |
Why?
|
| Inflammation | 5 | 2023 | 2915 | 0.070 |
Why?
|
| Time Factors | 3 | 2019 | 7079 | 0.070 |
Why?
|
| Linear Models | 2 | 2021 | 847 | 0.070 |
Why?
|
| Eye Diseases | 2 | 2020 | 98 | 0.060 |
Why?
|
| Antigen Presentation | 2 | 2005 | 209 | 0.060 |
Why?
|
| CD57 Antigens | 1 | 2007 | 18 | 0.060 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2008 | 186 | 0.060 |
Why?
|
| Fatal Outcome | 1 | 2008 | 302 | 0.060 |
Why?
|
| Prevalence | 2 | 2011 | 2852 | 0.060 |
Why?
|
| Antigens, CD | 2 | 2008 | 559 | 0.060 |
Why?
|
| Glutamate-Cysteine Ligase | 1 | 2006 | 19 | 0.060 |
Why?
|
| Total Lung Capacity | 1 | 2006 | 29 | 0.060 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2007 | 176 | 0.060 |
Why?
|
| Prospective Studies | 3 | 2025 | 8087 | 0.060 |
Why?
|
| Flow Cytometry | 3 | 2023 | 1160 | 0.060 |
Why?
|
| Protein Binding | 1 | 2012 | 2239 | 0.060 |
Why?
|
| Cell Separation | 2 | 2023 | 300 | 0.060 |
Why?
|
| Cell Line | 5 | 2013 | 2809 | 0.060 |
Why?
|
| B7-2 Antigen | 2 | 2017 | 27 | 0.060 |
Why?
|
| Netherlands | 2 | 2019 | 84 | 0.060 |
Why?
|
| Mice, Knockout | 2 | 2026 | 3121 | 0.060 |
Why?
|
| Chemical Industry | 1 | 2005 | 9 | 0.060 |
Why?
|
| Pesticides | 1 | 2025 | 59 | 0.060 |
Why?
|
| Peptides | 2 | 2026 | 991 | 0.060 |
Why?
|
| Cytoskeletal Proteins | 1 | 2025 | 146 | 0.050 |
Why?
|
| Pyrrolidines | 1 | 2025 | 126 | 0.050 |
Why?
|
| Nuclear Warfare | 1 | 2004 | 10 | 0.050 |
Why?
|
| Protein Structure, Secondary | 1 | 2005 | 357 | 0.050 |
Why?
|
| Endotoxemia | 1 | 2025 | 85 | 0.050 |
Why?
|
| Drug Combinations | 1 | 2025 | 399 | 0.050 |
Why?
|
| Ferritins | 1 | 2004 | 69 | 0.050 |
Why?
|
| Biomarkers, Tumor | 1 | 1991 | 1334 | 0.050 |
Why?
|
| Anastomotic Leak | 1 | 2024 | 45 | 0.050 |
Why?
|
| HLA-DRB3 Chains | 1 | 2003 | 2 | 0.050 |
Why?
|
| HLA-DRB5 Chains | 1 | 2003 | 2 | 0.050 |
Why?
|
| Molecular Docking Simulation | 1 | 2024 | 120 | 0.050 |
Why?
|
| HLA-DRB4 Chains | 1 | 2003 | 6 | 0.050 |
Why?
|
| Dysbiosis | 1 | 2025 | 184 | 0.050 |
Why?
|
| Follow-Up Studies | 2 | 2017 | 5397 | 0.050 |
Why?
|
| Moths | 1 | 2024 | 45 | 0.050 |
Why?
|
| CX3C Chemokine Receptor 1 | 1 | 2023 | 19 | 0.050 |
Why?
|
| Sutures | 1 | 2024 | 66 | 0.050 |
Why?
|
| HLA-DQ beta-Chains | 1 | 2003 | 58 | 0.050 |
Why?
|
| Laparotomy | 1 | 2024 | 109 | 0.050 |
Why?
|
| Genomics | 2 | 2022 | 851 | 0.050 |
Why?
|
| HLA-DR alpha-Chains | 1 | 2023 | 5 | 0.050 |
Why?
|
| Protein Tyrosine Phosphatases | 1 | 2004 | 166 | 0.050 |
Why?
|
| Larva | 1 | 2024 | 242 | 0.050 |
Why?
|
| Phycobilins | 1 | 2023 | 4 | 0.050 |
Why?
|
| Phycocyanin | 1 | 2023 | 4 | 0.050 |
Why?
|
| Endothelium | 1 | 2023 | 119 | 0.050 |
Why?
|
| Gene Expression Regulation, Bacterial | 1 | 2025 | 337 | 0.050 |
Why?
|
| Decision Making | 1 | 2010 | 987 | 0.050 |
Why?
|
| Reference Standards | 1 | 2023 | 176 | 0.050 |
Why?
|
| Cobalt | 1 | 2002 | 50 | 0.050 |
Why?
|
| Tomography, Optical Coherence | 1 | 2024 | 277 | 0.050 |
Why?
|
| Aluminum | 1 | 2002 | 43 | 0.050 |
Why?
|
| Thorax | 1 | 2022 | 51 | 0.050 |
Why?
|
| alpha 1-Antitrypsin | 1 | 2023 | 104 | 0.050 |
Why?
|
| Granuloma, Respiratory Tract | 1 | 2002 | 13 | 0.050 |
Why?
|
| RNA, Messenger | 3 | 2024 | 2783 | 0.040 |
Why?
|
| Immunity, Active | 1 | 2002 | 8 | 0.040 |
Why?
|
| Iron Metabolism Disorders | 1 | 2021 | 6 | 0.040 |
Why?
|
| Myosins | 1 | 2022 | 131 | 0.040 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2025 | 392 | 0.040 |
Why?
|
| Potassium, Dietary | 1 | 2021 | 12 | 0.040 |
Why?
|
| Whole Body Imaging | 1 | 2021 | 29 | 0.040 |
Why?
|
| DNA Probes, HLA | 1 | 2001 | 1 | 0.040 |
Why?
|
| Diet Surveys | 1 | 2021 | 89 | 0.040 |
Why?
|
| Pyrazoles | 1 | 2025 | 516 | 0.040 |
Why?
|
| Indoles | 1 | 2025 | 509 | 0.040 |
Why?
|
| Dietary Fiber | 1 | 2021 | 59 | 0.040 |
Why?
|
| Epitopes | 1 | 2003 | 479 | 0.040 |
Why?
|
| Cells | 1 | 2021 | 24 | 0.040 |
Why?
|
| Antigens, Fungal | 1 | 2021 | 28 | 0.040 |
Why?
|
| Bronchiolitis | 1 | 2002 | 87 | 0.040 |
Why?
|
| Ligands | 1 | 2023 | 676 | 0.040 |
Why?
|
| Eosinophil Cationic Protein | 1 | 2021 | 9 | 0.040 |
Why?
|
| Oxygen Consumption | 1 | 2004 | 719 | 0.040 |
Why?
|
| HLA-DR3 Antigen | 1 | 2021 | 76 | 0.040 |
Why?
|
| Enzyme-Linked Immunospot Assay | 2 | 2011 | 40 | 0.040 |
Why?
|
| Administration, Oral | 2 | 2016 | 867 | 0.040 |
Why?
|
| Hybridomas | 1 | 2021 | 233 | 0.040 |
Why?
|
| CD28 Antigens | 2 | 2013 | 57 | 0.040 |
Why?
|
| Immunoglobulin M | 1 | 2022 | 284 | 0.040 |
Why?
|
| Chemokine CXCL9 | 1 | 2021 | 38 | 0.040 |
Why?
|
| Observational Studies as Topic | 1 | 2021 | 133 | 0.040 |
Why?
|
| Mining | 1 | 2001 | 36 | 0.040 |
Why?
|
| Click Chemistry | 1 | 2021 | 54 | 0.040 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2003 | 845 | 0.040 |
Why?
|
| Minimal Clinically Important Difference | 1 | 2021 | 35 | 0.040 |
Why?
|
| Bone Cements | 1 | 2021 | 39 | 0.040 |
Why?
|
| Fungal Proteins | 1 | 2021 | 137 | 0.040 |
Why?
|
| Chi-Square Distribution | 3 | 2011 | 511 | 0.040 |
Why?
|
| Th17 Cells | 1 | 2021 | 103 | 0.040 |
Why?
|
| Pharmaceutical Preparations | 1 | 2022 | 172 | 0.040 |
Why?
|
| Radiography | 1 | 2003 | 856 | 0.040 |
Why?
|
| CD11c Antigen | 1 | 2020 | 40 | 0.040 |
Why?
|
| Biomedical Engineering | 1 | 2020 | 30 | 0.040 |
Why?
|
| Serologic Tests | 1 | 2020 | 50 | 0.040 |
Why?
|
| Lymphadenopathy | 1 | 2020 | 8 | 0.040 |
Why?
|
| Mediastinum | 1 | 2020 | 23 | 0.040 |
Why?
|
| Fatigue Syndrome, Chronic | 1 | 2020 | 19 | 0.040 |
Why?
|
| Textiles | 1 | 2020 | 22 | 0.040 |
Why?
|
| Hypercalcemia | 1 | 2020 | 23 | 0.040 |
Why?
|
| Medical History Taking | 1 | 2020 | 116 | 0.040 |
Why?
|
| Communicable Disease Control | 1 | 2020 | 88 | 0.040 |
Why?
|
| Oxygen | 2 | 2022 | 996 | 0.040 |
Why?
|
| Receptors, Fc | 1 | 2020 | 54 | 0.040 |
Why?
|
| Stochastic Processes | 1 | 2020 | 64 | 0.040 |
Why?
|
| Self-Help Devices | 1 | 2020 | 24 | 0.040 |
Why?
|
| Cryosurgery | 1 | 2020 | 46 | 0.040 |
Why?
|
| Intersectoral Collaboration | 1 | 2020 | 64 | 0.040 |
Why?
|
| Aspartate Aminotransferases | 1 | 2020 | 86 | 0.040 |
Why?
|
| T-Box Domain Proteins | 1 | 2020 | 106 | 0.040 |
Why?
|
| Staphylococcal Infections | 1 | 2024 | 396 | 0.040 |
Why?
|
| Oleic Acids | 1 | 2019 | 12 | 0.040 |
Why?
|
| Prostheses and Implants | 1 | 2021 | 137 | 0.040 |
Why?
|
| Electrocardiography, Ambulatory | 1 | 2020 | 64 | 0.040 |
Why?
|
| Fractals | 1 | 2019 | 8 | 0.040 |
Why?
|
| Mobility Limitation | 1 | 2020 | 66 | 0.040 |
Why?
|
| Amino Acid Sequence | 3 | 2013 | 2088 | 0.040 |
Why?
|
| Models, Animal | 1 | 2021 | 386 | 0.040 |
Why?
|
| Radionuclide Imaging | 1 | 2019 | 116 | 0.040 |
Why?
|
| Autoantigens | 1 | 2022 | 426 | 0.040 |
Why?
|
| Animal Feed | 1 | 2019 | 50 | 0.040 |
Why?
|
| Receptors, Complement 3d | 1 | 2020 | 150 | 0.040 |
Why?
|
| Alanine Transaminase | 1 | 2020 | 151 | 0.040 |
Why?
|
| Tertiary Lymphoid Structures | 1 | 2019 | 7 | 0.040 |
Why?
|
| Alkaline Phosphatase | 1 | 2020 | 144 | 0.040 |
Why?
|
| Pulmonary Medicine | 1 | 2020 | 78 | 0.040 |
Why?
|
| Chemokine CXCL13 | 1 | 2019 | 15 | 0.040 |
Why?
|
| Pulmonary Surfactant-Associated Protein A | 1 | 2019 | 30 | 0.040 |
Why?
|
| Antidepressive Agents | 1 | 2021 | 234 | 0.040 |
Why?
|
| Receptors, Immunologic | 1 | 2020 | 210 | 0.040 |
Why?
|
| Pulmonary Surfactant-Associated Protein C | 1 | 2019 | 45 | 0.040 |
Why?
|
| GTPase-Activating Proteins | 1 | 2019 | 81 | 0.040 |
Why?
|
| Systole | 1 | 2019 | 179 | 0.040 |
Why?
|
| RNA, Bacterial | 1 | 2020 | 182 | 0.040 |
Why?
|
| Healthy Volunteers | 1 | 2019 | 217 | 0.040 |
Why?
|
| Mass Spectrometry | 1 | 2022 | 728 | 0.040 |
Why?
|
| Sequence Analysis, RNA | 1 | 2021 | 441 | 0.040 |
Why?
|
| Programmed Cell Death 1 Receptor | 2 | 2013 | 268 | 0.040 |
Why?
|
| Exoribonucleases | 1 | 2019 | 48 | 0.030 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2019 | 115 | 0.030 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2022 | 578 | 0.030 |
Why?
|
| Endosonography | 1 | 2020 | 160 | 0.030 |
Why?
|
| Electric Countershock | 1 | 2019 | 126 | 0.030 |
Why?
|
| Breast Neoplasms | 1 | 1991 | 2411 | 0.030 |
Why?
|
| Interleukin-2 | 2 | 2013 | 434 | 0.030 |
Why?
|
| Dietary Supplements | 1 | 2023 | 586 | 0.030 |
Why?
|
| Autoimmunity | 1 | 2004 | 924 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 1999 | 328 | 0.030 |
Why?
|
| Bile Acids and Salts | 1 | 2019 | 162 | 0.030 |
Why?
|
| Benchmarking | 1 | 2019 | 192 | 0.030 |
Why?
|
| Myeloid Differentiation Factor 88 | 1 | 2019 | 119 | 0.030 |
Why?
|
| Delphi Technique | 1 | 2020 | 347 | 0.030 |
Why?
|
| Creatinine | 1 | 2020 | 511 | 0.030 |
Why?
|
| DNA Helicases | 1 | 2019 | 138 | 0.030 |
Why?
|
| Receptor, Parathyroid Hormone, Type 1 | 1 | 2017 | 3 | 0.030 |
Why?
|
| Caenorhabditis elegans | 1 | 2021 | 329 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2022 | 1125 | 0.030 |
Why?
|
| Telomere-Binding Proteins | 1 | 2019 | 121 | 0.030 |
Why?
|
| Reoperation | 1 | 2021 | 633 | 0.030 |
Why?
|
| Janus Kinase 1 | 1 | 2017 | 26 | 0.030 |
Why?
|
| New York City | 1 | 2017 | 87 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2004 | 2018 | 0.030 |
Why?
|
| High Mobility Group Proteins | 1 | 2017 | 45 | 0.030 |
Why?
|
| Adaptor Proteins, Vesicular Transport | 1 | 2017 | 46 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2002 | 1062 | 0.030 |
Why?
|
| Chromosome Mapping | 2 | 2004 | 505 | 0.030 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2019 | 242 | 0.030 |
Why?
|
| Forecasting | 1 | 2019 | 386 | 0.030 |
Why?
|
| Endothelial Cells | 1 | 2023 | 876 | 0.030 |
Why?
|
| RNA Splicing Factors | 1 | 2017 | 66 | 0.030 |
Why?
|
| Lymph Nodes | 1 | 2020 | 511 | 0.030 |
Why?
|
| Epigenomics | 1 | 2017 | 123 | 0.030 |
Why?
|
| Base Sequence | 2 | 2014 | 2119 | 0.030 |
Why?
|
| Telomerase | 1 | 2019 | 252 | 0.030 |
Why?
|
| Child, Preschool | 2 | 2025 | 11888 | 0.030 |
Why?
|
| Echocardiography | 1 | 2020 | 645 | 0.030 |
Why?
|
| Mucin-5B | 1 | 2019 | 234 | 0.030 |
Why?
|
| Cross-Sectional Studies | 2 | 2011 | 5875 | 0.030 |
Why?
|
| Vitamin D | 1 | 2020 | 402 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 2019 | 771 | 0.030 |
Why?
|
| Poverty | 1 | 2020 | 530 | 0.030 |
Why?
|
| Stroke Volume | 1 | 2019 | 651 | 0.030 |
Why?
|
| Sleep Wake Disorders | 1 | 2020 | 314 | 0.030 |
Why?
|
| Brain Diseases | 1 | 1997 | 157 | 0.030 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2020 | 300 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2020 | 1323 | 0.030 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2017 | 232 | 0.030 |
Why?
|
| Defibrillators, Implantable | 1 | 2019 | 393 | 0.030 |
Why?
|
| Hospitals | 1 | 2020 | 730 | 0.030 |
Why?
|
| Mitochondrial Proteins | 1 | 2017 | 263 | 0.030 |
Why?
|
| Chronic Pain | 1 | 2020 | 302 | 0.030 |
Why?
|
| Quantitative Trait Loci | 1 | 2017 | 388 | 0.030 |
Why?
|
| Atherosclerosis | 1 | 2019 | 410 | 0.030 |
Why?
|
| Comorbidity | 1 | 2020 | 1652 | 0.030 |
Why?
|
| Autoantibodies | 1 | 2022 | 1498 | 0.030 |
Why?
|
| Molecular Sequence Data | 2 | 2014 | 2835 | 0.030 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2017 | 427 | 0.030 |
Why?
|
| Alcohol Drinking | 1 | 2021 | 847 | 0.030 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2017 | 456 | 0.030 |
Why?
|
| Software | 1 | 2019 | 673 | 0.030 |
Why?
|
| Repressor Proteins | 1 | 2017 | 428 | 0.030 |
Why?
|
| Protective Devices | 1 | 2014 | 28 | 0.030 |
Why?
|
| Calcium | 1 | 2020 | 1181 | 0.030 |
Why?
|
| United States Occupational Safety and Health Administration | 1 | 2013 | 6 | 0.020 |
Why?
|
| Health Personnel | 1 | 2020 | 750 | 0.020 |
Why?
|
| Heme Oxygenase-1 | 1 | 2014 | 76 | 0.020 |
Why?
|
| B7-1 Antigen | 1 | 2013 | 55 | 0.020 |
Why?
|
| Hematologic Tests | 1 | 2013 | 22 | 0.020 |
Why?
|
| Cardiac Imaging Techniques | 1 | 2013 | 24 | 0.020 |
Why?
|
| Lymphokines | 1 | 2013 | 127 | 0.020 |
Why?
|
| Gene Transfer, Horizontal | 1 | 2013 | 34 | 0.020 |
Why?
|
| Peptide Library | 1 | 2013 | 91 | 0.020 |
Why?
|
| Drug Resistance, Microbial | 1 | 2013 | 67 | 0.020 |
Why?
|
| Etanercept | 1 | 2012 | 60 | 0.020 |
Why?
|
| Immunity | 1 | 2013 | 140 | 0.020 |
Why?
|
| Infusions, Parenteral | 1 | 2012 | 47 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 2016 | 1075 | 0.020 |
Why?
|
| Colony Count, Microbial | 1 | 2012 | 90 | 0.020 |
Why?
|
| Phagocytes | 2 | 2004 | 79 | 0.020 |
Why?
|
| Interdisciplinary Communication | 1 | 2013 | 200 | 0.020 |
Why?
|
| Hyperplasia | 1 | 2012 | 164 | 0.020 |
Why?
|
| Microscopy, Immunoelectron | 1 | 1991 | 38 | 0.020 |
Why?
|
| Immunotoxins | 1 | 1991 | 51 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2024 | 2962 | 0.020 |
Why?
|
| Mammals | 1 | 2013 | 287 | 0.020 |
Why?
|
| Hypertension | 1 | 2020 | 1270 | 0.020 |
Why?
|
| Keratinocytes | 1 | 2012 | 190 | 0.020 |
Why?
|
| Program Development | 1 | 2013 | 365 | 0.020 |
Why?
|
| Ontario | 1 | 2011 | 91 | 0.020 |
Why?
|
| Self Report | 1 | 2015 | 869 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2011 | 345 | 0.020 |
Why?
|
| Gold | 1 | 1991 | 116 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2019 | 2446 | 0.020 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2011 | 143 | 0.020 |
Why?
|
| Plasmids | 1 | 1991 | 372 | 0.020 |
Why?
|
| Needs Assessment | 1 | 2013 | 403 | 0.020 |
Why?
|
| Regeneration | 1 | 2012 | 198 | 0.020 |
Why?
|
| Risk | 2 | 2004 | 917 | 0.020 |
Why?
|
| Japan | 1 | 2010 | 149 | 0.020 |
Why?
|
| Depression | 1 | 2020 | 1566 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2012 | 612 | 0.020 |
Why?
|
| Binding Sites | 1 | 2013 | 1306 | 0.020 |
Why?
|
| Educational Measurement | 1 | 2013 | 329 | 0.020 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2010 | 82 | 0.020 |
Why?
|
| CD3 Complex | 1 | 2010 | 112 | 0.020 |
Why?
|
| Antigen-Presenting Cells | 1 | 2009 | 161 | 0.020 |
Why?
|
| Transfection | 1 | 1991 | 914 | 0.020 |
Why?
|
| United Kingdom | 1 | 2010 | 376 | 0.020 |
Why?
|
| Blood Proteins | 1 | 2011 | 239 | 0.020 |
Why?
|
| Forkhead Transcription Factors | 1 | 2010 | 208 | 0.020 |
Why?
|
| Demography | 1 | 2009 | 274 | 0.020 |
Why?
|
| Program Evaluation | 1 | 2013 | 945 | 0.020 |
Why?
|
| 4-1BB Ligand | 1 | 2008 | 7 | 0.020 |
Why?
|
| Hypertension, Pulmonary | 1 | 2020 | 1957 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2011 | 1293 | 0.020 |
Why?
|
| Immunophenotyping | 1 | 2009 | 324 | 0.020 |
Why?
|
| Codon | 1 | 2007 | 92 | 0.020 |
Why?
|
| Adjuvants, Immunologic | 1 | 2008 | 243 | 0.020 |
Why?
|
| Fibrosis | 1 | 2009 | 568 | 0.020 |
Why?
|
| Obesity | 1 | 2020 | 3123 | 0.010 |
Why?
|
| Cell Survival | 1 | 2009 | 1102 | 0.010 |
Why?
|
| Transcription Factor AP-1 | 1 | 2006 | 76 | 0.010 |
Why?
|
| Gene Dosage | 1 | 2006 | 146 | 0.010 |
Why?
|
| Fibroblasts | 1 | 1991 | 1033 | 0.010 |
Why?
|
| Catalytic Domain | 1 | 2006 | 234 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2005 | 269 | 0.010 |
Why?
|
| RNA Precursors | 1 | 2006 | 155 | 0.010 |
Why?
|
| Caspase 8 | 1 | 2005 | 48 | 0.010 |
Why?
|
| Free Radical Scavengers | 1 | 2005 | 81 | 0.010 |
Why?
|
| Lymphocyte Count | 1 | 2005 | 166 | 0.010 |
Why?
|
| Metalloporphyrins | 1 | 2005 | 62 | 0.010 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2005 | 369 | 0.010 |
Why?
|
| Nuclear Family | 1 | 2004 | 50 | 0.010 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 1 | 1 | 2004 | 44 | 0.010 |
Why?
|
| Radioisotopes | 1 | 2004 | 37 | 0.010 |
Why?
|
| Caspases | 1 | 2005 | 233 | 0.010 |
Why?
|
| Species Specificity | 1 | 2005 | 542 | 0.010 |
Why?
|
| Kinetics | 1 | 2006 | 1553 | 0.010 |
Why?
|
| Infant | 1 | 2017 | 10093 | 0.010 |
Why?
|
| Reference Values | 1 | 2004 | 787 | 0.010 |
Why?
|
| Rats | 1 | 1991 | 5574 | 0.010 |
Why?
|
| Genes, T-Cell Receptor beta | 1 | 2002 | 22 | 0.010 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2002 | 120 | 0.010 |
Why?
|
| Biopsy, Needle | 1 | 2002 | 182 | 0.010 |
Why?
|
| Nuclear Proteins | 1 | 2006 | 739 | 0.010 |
Why?
|
| Incidence | 1 | 2008 | 2910 | 0.010 |
Why?
|
| Utah | 1 | 2001 | 82 | 0.010 |
Why?
|
| Oximetry | 1 | 2001 | 124 | 0.010 |
Why?
|
| Tetanus Toxoid | 1 | 2000 | 34 | 0.010 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2004 | 676 | 0.010 |
Why?
|
| Bromodeoxyuridine | 1 | 2000 | 74 | 0.010 |
Why?
|
| Lectins, C-Type | 1 | 2000 | 61 | 0.010 |
Why?
|
| Volatilization | 1 | 2000 | 45 | 0.010 |
Why?
|
| Scattering, Radiation | 1 | 2000 | 98 | 0.010 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 2000 | 106 | 0.010 |
Why?
|
| HLA-DP alpha-Chains | 1 | 1999 | 4 | 0.010 |
Why?
|
| Genetic Carrier Screening | 1 | 1999 | 31 | 0.010 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2000 | 127 | 0.010 |
Why?
|
| Dimerization | 1 | 1999 | 174 | 0.010 |
Why?
|
| Acute Disease | 1 | 2002 | 1033 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2006 | 1728 | 0.010 |
Why?
|
| Equipment Design | 1 | 2000 | 519 | 0.010 |
Why?
|
| Fluorescent Dyes | 1 | 2000 | 340 | 0.010 |
Why?
|
| Cell Movement | 1 | 2002 | 950 | 0.010 |
Why?
|
| Skin | 1 | 2002 | 701 | 0.010 |
Why?
|
| Light | 1 | 2000 | 400 | 0.010 |
Why?
|